Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
The FDA has cleared their once-weekly Factor VIII replacement therapy Altuviiio (efanesoctocog alfa) for adults and children with haemophilia A, giving Sanofi and Sobi a successor to well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results